Biomarker Modeling of Alzheimer’s Disease  by Jack, Clifford R. & Holtzman, David M.
Neuron
ReviewBiomarker Modeling of Alzheimer’s DiseaseClifford R. Jack, Jr.1,* and David M. Holtzman2,*
1Department of Radiology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
2Department of Neurology, Hope Center for Neurological Disorders, and Knight Alzheimer’s Disease Research Center,
Washington University, 660 S. Euclid Avenue, St. Louis, MO 63110, USA
*Correspondence: jack.clifford@mayo.edu (C.R.J.), holtzman@neuro.wustl.edu (D.M.H.)
http://dx.doi.org/10.1016/j.neuron.2013.12.003
Alzheimer’s disease (AD) is a slowly progressing disorder in which pathophysiological abnormalities, detect-
able in vivo by biomarkers, precede overt clinical symptoms by many years to decades. Five AD biomarkers
are sufficiently validated to have been incorporated into clinical diagnostic criteria and commonly used in
therapeutic trials. Current AD biomarkers fall into two categories: biomarkers of amyloid-b plaques and of
tau-related neurodegeneration. Three of the five are imaging measures and two are cerebrospinal fluid
analytes. AD biomarkers do not evolve in an identical manner but rather in a sequential but temporally
overlapping manner. Models of the temporal evolution of AD biomarkers can take the form of plots of
biomarker severity (degree of abnormality) versus time. In this Review, we discuss several time-dependent
models of AD that take into consideration varying age of onset (early versus late) and the influence of aging
and co-occurring brain pathologies that commonly arise in the elderly.Pathological Features of Alzheimer’s Disease
Two well-known abnormal protein aggregates characterize
Alzheimer’s disease (AD) pathologically (Hyman et al., 2012).
The hallmarks of amyloid-b (Ab) deposits in AD are neuritic
plaques and cerebral amyloid angiopathy (CAA). Neuritic
plaques are extracellular and consist of a dense central fibrillar
Ab core with inflammatory cells and dystrophic neurites in
its periphery. CAA is also extracellular and consists of
fibrillar Ab deposited in the wall of arterioles in both the
leptomeninges and penetrating vessels (Johnson et al.,
2007). The second major proteinopathy is aggregated tau,
which are intracellular aggregates of hyperphosphorylated
tau in the form of neurofibrillary tangles (NFTs). NFTs follow a
stereotypic topographic progression pattern, first appearing
in the brainstem and transentorhinal area, then progressing
to the hippocampus, to paralimbic and adjacent medial-basal
temporal cortex, to cortical association areas, and last to
primary sensory-motor and visual areas (Braak and Braak,
1991). Another important pathological feature is neurode-
generation, which maps onto NFT distribution topographically
(not onto b-amyloid distribution) and is characterized macro-
scopically as atrophy and microscopically as loss of neurons
and neuronal processes (Braak and Braak, 1994; Terry et al.,
1991).
Clinical-autopsy correlation studies demonstrate a much
tighter correlation between NFT and cognitive impairment than
between amyloid and cognitive impairment (Bennett et al.,
2004; Dickson et al., 1995; Go´mez-Isla et al., 1997; Ingelsson
et al., 2004). The tightest correlation between cognitive impair-
ment and various autopsy features of AD though seems to be
with neurodegeneration (Savva et al., 2009), specifically synapse
loss (Terry et al., 1991). Approximately 30%of cognitively normal
elderly subjects have sufficient pathology to meet criteria for AD
at autopsy (Knopman et al., 2003; Price and Morris, 1999); how-
ever, absence of cognitive symptoms is rarely seen in individuals
with severe NFT burden.Heterogeneity of Brain Pathology in Older Adults
The accumulation of brain pathologies seems to be a nearly inev-
itable consequence of aging; very few elderly individuals have no
findings at autopsy and the older the individual the more this
holds true (Nelson et al., 2011). The common age-associated
brain pathologies are AD (plaques and tangles), medial temporal
tangles without plaques, ischemic cerebrovascular disease
(which includes not onlymacroscopic cortical and subcortical in-
farctions but also microinfarctions, which seem to be particularly
important, and ischemic demyelination), hippocampal sclerosis,
alpha synuclein deposits (Lewy bodies), TDP43 inclusions, and
agyrophyllic grains (Markesbery et al., 2006; Schneider et al.,
2009; Sonnen et al., 2011;White, 2009). These same pathologies
are also found in subjects who were cognitively normal at the
time of death, albeit usually at lower overall pathological burdens
than in demented subjects. Themost common finding at autopsy
in elderly persons who meet clinical and pathological criteria for
AD dementia is mixed pathology—plaques and tangles plus one
or more of the non-AD pathologies above. Throughout this paper
therefore, AD is discussed from two perspectives: early onset,
which is a reasonable model of ‘‘pure AD,’’ and late onset, which
usually consists of AD plus one or more co-occurring patholog-
ical processes.
AD Pathogenesis: Early-Onset versus Late-Onset AD
Early-Onset AD
AD is commonly categorized clinically as either early onset
(onset of clinical symptoms before age 65) or late onset. Early-
onset AD is uncommon, accounting for a few percent of cases
at most. A proportion of early-onset AD cases occur in individ-
uals with autosomal-dominant mutations in one of three genes:
the amyloid precursor protein gene on chromosome 21, the
presenilin-1 gene on chromosome 14, or the presenilin-2 gene
on chromosome 1 (Goate et al., 1991; Levy-Lahad et al., 1995;
Sherrington et al., 1995; St George-Hyslop et al., 1987). Along
with Down syndrome, all known autosomal-dominant mutationsNeuron 80, December 18, 2013 ª2013 Elsevier Inc. 1347
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tein (APP) in a manner resulting in (1) increased production of
Ab42 or all Ab species or (2) increased aggregation/decreased
clearance of Ab (Holtzman et al., 2011). These result in increasing
the accumulation of oligomeric and fibrillar Ab (Scheuner et al.,
1996).
It is notable that primary tauopathies lead to forms of fronto-
temporal lobar degeneration, corticobasal degeneration, and
progressive supranuclear palsy but never to pathological AD
(i.e., not to Ab accumulation). Animal models in which human
amyloid precursor protein with or without presenilin mutations
have been inserted into the mouse genome recapitulate the
Ab-linked aspects seen in autosomal-dominant AD, including
increased CSF tau (Maia et al., 2013). Transgenic mouse models
of b-amyloidosis and cellular evidence indicate that Ab exacer-
bates tauopathy (Lewis et al., 2001; Oddo et al., 2004) (perhaps
by kindling the autopropagation of NFTs [Clavaguera et al., 2009;
de Calignon et al., 2012; Frost et al., 2009; Guo and Lee, 2011]),
not the reverse (Oddo et al., 2003). The available genetic
evidence points to Ab overproduction of all Ab species
(APP duplication, APP Swedish mutation), relative Ab42 versus
Ab40 overproduction (N-terminal APP mutations/presenilin
mutations), or enhanced aggregation/decreased clearance
(APP mutations within the Ab domain) as causative in autosomal
dominate AD (Holtzman et al., 2011). This has led to the amyloid
cascade hypothesis, which asserts that dysfunction in the
Ab pathway is the initiating event in the disease (Glenner and
Wong, 1984; Hardy and Selkoe, 2002). Soluble Ab, rather
than insoluble Ab, is felt to initiate the disease cascade (Hardy,
2009). A simple mechanistic diagram of the amyloid cascade
hypothesis is shown below:
over production/aggregation of Ab42/ tauopathy/ neuro-
degeneration/ clinical symptoms.
Late-Onset AD
Late-onset AD accounts for the overwhelming majority of cases.
While most autosomal-dominant AD is believed to usually be
caused by overproduction and subsequent aggregation of
Ab42 (a more fibrillogenic form of Ab) from the beginning of life,
late-onset AD may most often be a disease of inadequate Ab
clearance, again leading to increased aggregation and accumu-
lation (Mawuenyega et al., 2010). While deterministic genetic
mutations for sporadic AD have not been found, genetics none-
theless plays a very important role in risk. The ε4 allele of the
apolipoprotein E (APOE) gene is the major known genetic risk
factor (Roses, 1994). The ε4 allele of APOE increases the risk
of developing AD and also lowers the mean age at onset of the
disease in a dose-dependent fashion (Corder et al., 1993; Stritt-
matter et al., 1993). The major mechanism by which APOE ε4
contributes to AD pathogenesis appears to be by modulating
the aggregation and clearance of Ab peptide (Castellano et al.,
2011; Kim et al., 2009), leading to increased deposition (Morris
et al., 2010; Vemuri et al., 2010), which implicates this pathway
in causation of late-onset AD. However, APOE is also implicated
in many functions other than Ab trafficking that may contribute to
AD pathogenesis, including regulating brain lipid metabolism,
neuronal repair, synaptic function, inflammation, and mitochon-
drial function (Bu, 2009; Mahley and Huang, 2009). The effect of
any specific genetic variant other than APOE4 at the population1348 Neuron 80, December 18, 2013 ª2013 Elsevier Inc.level is minor. Risk variants, including those of CLU, CR1,
PICALM, CD33, APP, A673T, ABCA7, EPHA1, TREM 2,
SORL1, and BIN1, do point to Ab but also to alternative path-
ways including immunologic, inflammatory, neurotropic, endo-
cytosis, cholesterol metabolism, ubiquitination, and tau (Bertram
et al., 2008; Griciuc et al., 2013; Guerreiro et al., 2013; Harold
et al., 2009; Hollingworth et al., 2011; Jonsson et al., 2013;
Lambert et al., 2009; Naj et al., 2011; Seshadri et al., 2010).
Thus, from a genetics standpoint, sporadic AD is complex.
Late-onset AD is also more complex than early onset from a
pathological perspective. As noted above, late-onset AD typi-
cally occurs along with other age-related pathologies. In fact,
the contribution of pathologies such as hippocampal sclerosis
and cerebrovascular disease to dementia seems to increase
relative to AD pathology with advancing age beyond 85 years
(Nelson et al., 2011). A further complicating factor is the fact
that subcortical andmedial temporal tauopathy exists at autopsy
very commonly by middle age in individuals who have no
plaques (Braak and Braak, 1997; Braak and Del Tredici, 2011;
Haroutunian et al., 1999; Price and Morris, 1999). For example,
in autopsies numbering in the thousands, Braak and Braak
(Braak and Braak, 1997) find that by the late 70s, nearly all indi-
viduals (97%) have some tauopathy, while only 17% have b-am-
yloid deposits. The fact that brainstem and medial temporal lobe
tau commonly precedes amyloid plaques has led some to sug-
gest that a different pathogenic model should exist for late-onset
versus early-onset AD.
Role of Ab in Pathogenesis of AD
The initiating event in the molecular cascade that eventually
leads to clinical and pathological AD has been controversial
for decades. The amyloid cascade hypothesis (Glenner and
Wong, 1984; Hardy and Selkoe, 2002) assumes serial causal
events initiated by abnormal Ab production/aggregation. As dis-
cussed above, this seems to be a reasonable pathogenic model
of early-onset AD. An alternative position is that tau hyperphos-
phorylation and Ab elevation are independently arising patho-
physiological processes that interact with pathogenic synergy
(Duyckaerts, 2011; Duyckaerts et al., 1997; Mesulam, 1999;
Small and Duff, 2008), which is particularly germane to late-onset
AD (Che´telat, 2013; Desikan et al., 2011; Jack et al., 2013a;
Knopman et al., 2012, 2013). A sequence of pathological events
proposed by Price and Morris (1999) for late-onset AD seems to
best explain the fact that while small amounts of medial temporal
tauopathy often precede amyloid plaque formation, Ab seems to
drive the progression of the disease. Price andMorris (1999) pro-
pose that tauopathy develops first but is confined to subcortical
andmedial temporal limbic areas, is clinically benign, and is best
thought of as a feature of typical aging. Neocortical Ab deposits
develop later, independently from medial temporal tauopathy.
By unknown mechanism(s), distant Ab aggregation transforms
the medial temporal tauopathy leading to spread from medial
temporal limbic areas to widespread extension throughout the
neocortex. The proposed relationship between cognition and
amyloid in late-onset AD is not predominantly due to direct
neurotoxicity of aggregated Ab, but rather to its role in aiding
the propagation of an antecedent tau-related neurodegeneration
throughout a topographically characteristic susceptible network
Figure 1. Voxel-Based Comparisons of Amyloid PET, FDG PET, and
Structural MRI Illustrate Differences between Subjects with
Alzheimer’s Disease and Cognitively Normal Elderly
AD (n = 50) and cognitively normal elderly subjects (n = 50) were from theMayo
Clinic and were matched on age and gender.
(A) Amyloid PET maps (thresholded at FWE, p < 0.001 without partial volume
correction) illustrate greater retention of Pittsburgh Compound B (PIB) in AD
versus cognitively normal elderly in most brain areas; primary sensory-motor,
visual, and medial temporal lobe are spared.
(B) FDG PET maps (thresholded at FWE, p < 0.001 without partial volume
correction) illustrate decreased FDG uptake in the basal temporal, lateral
temporal-parietal, lateral prefrontal, and posterior cingulate-precuneus in AD
compared to cognitively normal elderly. This spatial pattern constitutes an ‘‘AD
signature’’ in FDG PET.
(C) Structural MRI maps (thresholded at FWE, p < 0.05) illustrate gray matter
loss in the medial, basal, and lateral temporal, lateral parietal, occipital, insula,
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eration that is ultimately responsible for clinical symptoms
(a position reinforced by the poor association between the topo-
graphic distribution of amyloid and clinical phenotype in atypical
forms of AD [Rabinovici et al., 2008; Wolk et al., 2012]). This view
does not conflict with the amyloid cascade hypothesis in that it
acknowledges the central role of Ab in disease pathogenesis.
As outlined in a recent review (Jack et al., 2013a) and in the
section on AD pathogenesis, while tauopathy and Abothapy
may arise independently, evidence suggests that Ab drives tau
pathology, not the reverse. This view also does not imply that
therapeutic interventions targeting Ab in late-onset disease are
misguided, given the essential role Ab plays in pathogenesis in
late-onset (as well as early-onset) AD.
AD Biomarkers
A biomarker is a physiological, biochemical, or anatomic param-
eter that can be objectively measured as an indicator of normal
biologic processes, pathological processes, or responses to a
therapeutic intervention. At present five AD biomarkers are well
enough established to be used in clinical trials and in modern
diagnostic criteria (Albert et al., 2011; Dubois et al., 2010; Jack
et al., 2011a; McKhann et al., 2011; Sperling et al., 2011a). Two
of these are cerebrospinal fluid (CSF) proteins and three are
brain imagingmeasures. These fivebiomarkers fall into twomajor
mechanistic categories. First are measures of Ab deposition:
these are CSF Ab42, which decreases with increasing amyloid
plaque load (Bouwman et al., 2009; Fagan et al., 2007; Mattsson
et al., 2009; Shaw et al., 2009; Visser et al., 2009), and positron
emission tomography (PET) amyloid imaging (Drzezga, 2010;
Klunk et al., 2004; Nordberg et al., 2013; Rodrigue et al., 2012;
Rowe et al., 2010; Villemagne et al., 2011) (Figure 1A). These
two biomarkers of amyloid are highly correlated when measured
in the same individuals (Fagan et al., 2006; Jagust et al., 2009;
Tolboom et al., 2009; Weigand et al., 2011). The validity of these
biomarkers of amyloid plaque deposition has been established
by autopsy correlation studies (Clark et al., 2011; Fleisher et al.,
2011; Ikonomovic et al., 2008; Sojkova et al., 2011; Strozyk
et al., 2003; Tapiola et al., 2009).
The second major AD biomarker category is neurodegenera-
tion, defined as progressive loss of neurons and their processes
with a corresponding progressive impairment in neuronal func-
tion. The three major AD neurodegnerative biomarkers are
increased levels of CSF total (t-tau) and phosphorylated (p-tau)
tau (Fagan et al., 2009; Mattsson et al., 2009; Shaw et al., 2009;
Visser et al., 2009), atrophy on structural MRI (Desikan et al.,
2009; Dickerson and Wolk, 2012; Hua et al., 2008; Morra et al.,
2008, 2009; Vemuri et al., 2009), and hypometabolism on FDG
PET (Jagust et al., 2010). The validity of these biomarkers of neu-
rodegeneration due to AD is supported by autopsy correlation
studies. A caveat is that direct tissue-to-image correlation can
be established between tissue stains and in vivo or ex vivoand precuneus in AD compared to cognitively normal elderly. This spatial
pattern constitutes an ‘‘AD signature’’ in structural MRI. All voxel-wise
comparisons generated with SPM5. 3D displays are by Brain Net Viewer
(http://www.nitrc.org/projects/bnv/). The color bar scale indicates the t test
differences between the groups.
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CSF analytes. Elevations in t-tau (Tapiola et al., 2009) and p-tau
(Buerger et al., 2006; Tapiola et al., 2009) correlate with neurofi-
brillary tangle (NFT) burdenat autopsy. AtrophyonMRIcorrelates
with neuron loss (Bobinski et al., 2000; Zarow et al., 2005), Braak
NFT stage (Jack et al., 2002; Vemuri et al., 2008; Whitwell et al.,
2008), and tau immunostaining burden (Whitwell et al., 2008)
and does not correlate well with Ab load measured by immuno-
histochemistry (Josephs et al., 2008). Thus, MRI is a measure
of tau-associated neurodegeneration. Antemortem FDG hypo-
metabolism is also correlated to NFT burden and not to plaque
burden at autopsy (DeCarli et al., 1992).
An important distinction between biomarkers of Ab deposition
and biomarkers of neurodegeneration concerns their specificity
for AD pathophysiology. CSF Ab42 and amyloid PET are specific
for fibrillar b-amyloid deposition (in the extracellular space or in
vessel walls). In contrast, neurodegenerative biomarkers are
not always specific for neurodegeneration due to AD (Jack
et al., 2002). In subjects with AD, both FDG PET and MRI follow
a modality-specific topology that is characteristic of AD (Figures
1B and 1C). An FDG PET or MRI study is transformed into a
quantitative biomarker by extracting and summing values from
AD-signature regions (as illustrated in Figures 1B and 1C) using
an anatomic atlas that is spatially registered to the subject’s
imaging study (Senjem et al., 2005). However, atrophy and
FDG hypometabolism caused by non-AD etiologies can overlap
spatially with these AD-like topographic patterns. Non-AD etiol-
ogies associated with atrophy, FDG hypometabolism, or both
that commonly occur in elderly people include cerebrovascular
disease, hippocampal sclerosis, non-AD degenerative disorders
such as Lewy body disease, grain disease, and perhaps TDP43.
A feature of most automated image analysis algorithms that
contributes to the nonspecificity of MRI and FDG is that the
algorithms typically interrogate only a modality-specific AD-like
topographic pattern and do not examine areas outside of this
predefined topology. Elevation of CSF tau (particularly p-tau)
seems to be more specific for AD—i.e., it is not elevated in
primary tauopathies—however, total tau is elevated in Creutzfelt
Jakob disease, head trauma, and acute stroke. Thus, the inter-
pretation of these neurodegenerative biomarkers in empiric
studies of elderly subjects is confounded by overlap with
co-occurring pathologies that ideally should be distinguished
from AD. The importance of this will become evident when
discussing modeling of biomarker evolution.
Other potential biomarkers of AD exist at various stages of
evaluation. These include other CSF analytes such as VILIP-1
(Tarawneh et al., 2011) diffusion MRI, perfusion MRI, functional
MRI (both resting state or task-free and task activation MRI),
and tau PET ligands. These are either very new or have not yet
demonstrated the test retest precision or the diagnostic efficacy
to be considered a major biomarker. This may change with
further development and testing.
Temporal Evolution of AD Biomarkers
Models of the temporal evolution of AD biomarkers can take the
form of plots of biomarker severity (degree of abnormality)
versus time (Figure 2). For imaging biomarkers (Figure 1), move-
ment up the y axis in Figure 2 corresponds to both topographic1350 Neuron 80, December 18, 2013 ª2013 Elsevier Inc.progression as well as increasing severity in brain areas that are
already involved. This type of plot illustrates two key types of
relationships in a single display. First is the shape of each
biomarker curve as a function of time (i.e., functional form).
Biomarkers could increase linearly with time, exponentially,
sigmoidally, etc. (Fjell et al., 2013b). Different shapes carry
different implications concerning the biological mechanisms
driving the observed changes in a biomarker with time. The
second key relationship concerns the temporal ordering of bio-
markers with respect to each other and to the evolution of clinical
symptoms. Modeling biomarker trajectories as curves that are
time shifted relative to one another reflects the notion that the
different underlying pathophysiologic processes do not evolve
simultaneously at identical rates but rather in a temporally
ordered manner. A model of biomarker evolution with time
depends on both the biology underlying biomarker changes
and the sensitivity and specificity of the biomarkers to the biolog-
ical signals that each responds to. We emphasize that biology
(the order and rates of pathophysiological events) and technol-
ogy (ability to detect events) are inseparable aspects of the appli-
cation of biomarkers for human use. For example, it is entirely
possible that a highly sensitive biomarker of a later occurring
pathological process may become abnormal before a relatively
insensitive biomarker of an earlier pathological process.
Initial models of the temporal evolution of AD biomarkers were
based on observations in elderly subjects spanning the cognitive
continuum (Jack et al., 2008, 2009, 2010a; Mormino et al., 2009;
Perrin et al., 2009) and were supported by earlier autopsy data
(Ingelsson et al., 2004). These initial models proposed that
amyloid biomarkers become abnormal first, then biomarkers of
tau-related neurodegeneration, followed last by overt clinical
symptoms. One model took the additional step of proposing
not only an ordering scheme but also that the general shape
or functional form for biomarker evolution was sigmoidal with
time (Jack et al., 2010a). Following publication of these initial
biomarkermodels, subsequent empiric studies in both elderly in-
dividuals (Buchhave et al., 2012; Fo¨rster et al., 2012; Jack et al.,
2010b, 2011b; Landau et al., 2012; Lo et al., 2011; Villemagne
et al., 2011, 2013) and in carriers of autosomal-dominant muta-
tions (Bateman et al., 2012; Reiman et al., 2012) found that
ordering of biomarkers was generally consistent with that pro-
posed in the models. In addition, empirical data has confirmed
that at least one class of biomarkers—b-amyloid—does follow
a sigmoidal shape with time (Caroli and Frisoni, 2010; Fleisher
et al., 2012; Jack et al., 2012b, 2013b; Villain et al., 2012; Ville-
magne et al., 2013). Given that late stage AD subjects have not
been thoroughly studiedwith biomarkers to date, it is not surpris-
ing that convincing evidence for plateauing (i.e., sigmoidal shape)
has only been found for the earliest changing class of AD
biomarkers (b-amyloid).
The discussion in the previous sections though suggests that
different models might exist for early-onset versus late-onset AD
primarily because cognitive and neurodegenerative biomarker
abnormalities due to non-AD pathologies and to aging all may
precede or co-occur with AD pathology in the elderly. We pro-
pose that three different sets of biomarker models should be
considered, each of which culminates in the common clinical
phenotype of AD dementia.
Figure 2. Temporal Evolution of Biomarkers
(A) Biomarker model of pure AD. The horizontal
axis represents time and the vertical axis severity
of biomarker abnormality from completely normal
(min) to abnormal (max). The threshold for
biomarker detection of pathophysiology is de-
noted by a horizontal black line. The gray area
denotes the zone in which abnormal patho-
physiology lies below the biomarker detection
threshold. Amyloid biomarkers become abnormal
first, followed by CSF tau, followed by FDG PET
and MRI. Cognitive impairment (green filled area)
is the last event in the progression of the disease. A
range of cognitive responses are possible that
depend on the individual’s risk profile. The cogni-
tive response curve is shifted to the left for those
with low cognitive reserve and to the right for those
with high cognitive reserve. At a given point on
the disease time line, a person with high cognitive
reserve can be cognitively normal while a low
cognitive reserve person with the same biomarker
profile is impaired. All biomarker curves (as well
as cognitive impairment) are configured as sig-
moids, but the curves have a progressively
steeper slope in the right-hand tail for later-
changing biomarkers. The right hand tails of the
curves are dashed, indicating that biomarker
trajectories in end-stage dementia are unknown at
this time. MCI, mild cognitive impairment.
(B) Amyloid-first biomarker model of late-onset
AD where comorbid pathologies are likely.
Figure labels are as in (A), except here the CSF tau,
structural MRI, and FDG PET are grouped under
the generic neurodegenerative label. This reflects
the fact that neurodegenerative biomarkers can be
nonspecific and that the proportional contribution
of various possible neurodegenerative processes
cannot be known in vivo. We assume that in most
elderly individuals, tauopathy, non-AD neurode-
generative pathologies, or both arise first but lie
beneath the detection threshold of biomarkers of
neurodegeneration. Abopathy arises later inde-
pendently and b-amyloid biomarkers become
abnormal first. The neurodegeneration curve has a
shallow slope initially but steepens after the onset
of b-amyloidosis.
(C) Neurodegeneration-first biomarker model of
late-onset AD where comorbid pathologies are
likely. Figure labels are as in (A), except here one or
more neurodegenerative biomarkers become
abnormal first, reflecting the onset of tauopathy,
other neurodegenerative pathologies, or both prior
to b-amyloid. Observing the onset of an abnormal
neurodegenerative biomarker prior to an abnormal
amyloid biomarker does not alter the role of
b-amyloid as an inducer of neurodegeneration.
This is indicated by showing the neuro-
degeneration curve with a shallow slope initially,
which steepens after the onset of b-amyloidosis.
Adapted with permission from Jack et al. (2013a).
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The concept of pathologically pure AD (i.e., in the absence of
non-AD age-related pathologies) seems appropriate with onsetNeuron 80, Deearly in life when non-AD age-related pa-
thologies are not highly prevalent. This is
usually the case in autosomal-dominant
AD and many APOE4 homozygotes. A
model of the temporal ordering of thefive major AD biomarkers for early-onset AD is outlined in text
below and is illustrated in Figure 2A. The temporal ordering
scheme in this biomarker model of ‘‘pure’’ AD matches thecember 18, 2013 ª2013 Elsevier Inc. 1351
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hypothesis (Glenner and Wong, 1984; Hardy and Selkoe, 2002).
1. Ab 42 overproduction and aggregation/decreased clear-
ance leads to amyloid plaque formation. CSF Ab 42 and
amyloid PET are the first biomarkers to become abnormal.
2. Abopathy induces a medial temporal tauopathy and
promotes its spread into the neocortex. CSF tau then be-
comes abnormal. In some cases, Abopathy also induces
synuclein aggregation as well.
3. Tauopathy leads to detectable abnormalities in imaging
biomarkers of neurodegeneration—structural MRI and
FDG PET.
4. Clinical symptoms follow theMRI and FDGPET abnormal-
ities (Reed et al., 2010; Vemuri et al., 2011).
5. In the early to midclinically symptomatic phases of the dis-
ease, amyloid biomarkers approach a plateau while MRI,
FDG PET, and tau continue to increase.
6. In the end stage of the disease, we hypothesize that all bio-
markers approach a plateau; however, this is conjecture.
Patients can live for many years after they are no longer
able to participate in research studies. In this end stage,
patients may survive for prolonged periods unresponsive
and bed ridden with little external evidence of further dis-
ease progression. Systematic studies of biomarker pro-
gression in this stage of the disease have not been done
and are difficult to perform. Hence, the right-hand portions
of all biomarker curves in Figure 2 are drawn as dotted
lines, indicating lack of knowledge about the terminal
phase of the disease.
Late-Onset AD Biomarker Models
Modeling late-onset AD differs from early-onset AD in
several important ways. First, AD pathophysiology commonly
coexists with age-related non-AD pathologies discussed above
(Schneider et al., 2007, 2009). Second neurodegenerative
changes may occur as a function of aging in the absence of
any specific disease process, akin to well-documented age-
related declines in other organ systems likemusclemass or renal
perfusion (Fjell et al., 2013a; Jagust, 2013). Brain systems partic-
ularly vulnerable to aging seem to be those subserving attention/
executive function and declarative memory (Jagust, 2013). A
candidate substrate for age-related declines in cognitive func-
tion, brain volumes, and FDG PET uptake in the absence of spe-
cific pathologies is synapse loss (Jagust, 2013; Yeoman et al.,
2012). Thus, unlike early-onset AD, late-onset AD commonly ex-
ists on a background of neurodegenerative changes due to ag-
ing, non-AD pathologies, or both (Jack et al., 2010b). Third, a
phenomenon that has been recognized by a number of investi-
gators is that biomarkers of neurodegeneration (especially struc-
tural MRI and FDG PET) are not specific for AD and may show
AD-like patterns of abnormality due to non-AD conditions (Dick-
erson andWolk, 2012; Fjell et al., 2013a; Jack et al., 2002, 2010a,
2010b, 2012a, 2013a; Jagust, 2013; Raz et al., 2007; Wirth et al.,
2013a, 2013b). A corollary to this is that validated biomarkers of
neurodegeneration that are specific for non-AD pathologies are
lacking. Therefore, in any given person, we cannot know the pre-
cise pathological etiologies underlying an abnormal structural1352 Neuron 80, December 18, 2013 ª2013 Elsevier Inc.MRI or FDG PET scan or the proportional contribution of various
possible etiologies to neurodegeneration (Jack et al., 2010b).
Realistic interpretation of neurodegenerative biomarkers in the
elderly should acknowledge that many possible etiologies and
proportional mixes of etiologies may contribute to an abnormal
neurodegenerative biomarker finding. The reason modeling of
AD biomarkers seems to work empirically in the elderly is
because AD is the dominant pathology leading to dementia.
While considerable evidence, described earlier under ‘‘tempo-
ral evolution of AD biomarkers,’’ supports an amyloid-first
biomarker model of late-onset AD, evidence has also appeared
that supports the idea that cognitive decline and neurodegener-
ative biomarker abnormalities might precede abnormal amyloid
biomarkers in some elderly individuals who later develop AD.
This evidence falls into three categories. First, autopsy studies
indicate that by late 50s, two-thirds of the population and by
the late 70s essentially everyone has some degree of medial
temporal tauopathy, very often without amyloid plaques (Braak
and Braak, 1997). Therefore, tauopathy ought to precede amy-
loid in many individuals who eventually develop late-onset AD
(Braak and Braak, 1997; Haroutunian et al., 1999; Price andMor-
ris, 1999). While we currently lack in vivo data on the topographic
staging of tau akin to Braak staging (Braak and Braak, 1997), this
will probably be remedied in the future by new PET tau ligands
(Chien et al., 2013; Fodero-Tavoletti et al., 2011; Maruyama
et al., 2013). Second, FDG PET and functional MRI studies
have identified AD-like imaging abnormalities in cognitively
normal APOE4 carriers (compared to noncarriers) who were
either too young to be amyloid positive (Filippini et al., 2009;
Reiman et al., 2004) or who were documented to be amyloid
negative (Jagust and Landau, 2012; Sheline et al., 2010). These
APOE4 carriers are much more likely to develop AD in the future
than noncarriers. While these studies are suggestive, they do
not prove that neurodegenerative abnormalities can precede
amyloidosis in individuals who do develop incident preclinical
AD; that requires longitudinal documentation of incident amyloid
positivity. To that end, a longitudinal study has recently proved
that MRI and FDG PET can be abnormal in AD-like areas prior
to documented indicant amyloid positivity in the elderly (Jack
et al., 2013c). This study (Jack et al., 2013c) has demonstrated
empirically that both ‘‘amyloid-first’’ and ‘‘neurodegeneration-
first’’ biomarker profile pathways to preclinical AD exist. We
therefore describe both amyloid-first and neurodegeneration-
first models of late-onset AD below.
The sequence of molecular and biomarker events in our pro-
posed ‘‘amyloid-first’’ model of late-onset AD is illustrated in
Figure 2B and outlined below.
1. Neurodegeneration due to tauopathy, non-AD pathol-
ogies, aging, or a combination first appears in the
brainstem and medial temporal lobe but lies beneath the
detection threshold of biomarkers of neurodegeneration.
2. Ab deposition arises later and progresses independently in
neocortical association areas. Ab biomarkers (CSF Ab42
and amyloid PET) then become positive.
3. Abopathy transforms slowly progressing medial temporal
tauopathy into an aggressive process and induces its
spread into the neocortex (Clavaguera et al., 2009; de
Neuron
ReviewCalignon et al., 2012; Frost et al., 2009; Guo and Lee,
2011; Price andMorris, 1999). One ormore neurodegener-
ative biomarkers then become abnormal. Because in any
older subject we cannot know whether AD pathology exits
in isolation or is accompanied by coexisting neurode-
generative processes, we group all neurodegeneration
biomarkers together under a single generic neurodegener-
ation heading in this model without attempting to distin-
guish tau- from non-tau-related etiologies (which is
different from the model of early-onset AD in which CSF
tau and MRI/PET are treated distinctly because non-AD
pathology is unlikely to be present). The accelerating ef-
fect of amyloid on neurodegeneration is illustrated in the
neurodegeneration curve that has a shallow slope initially
but steepens after the onset of amyloidosis.
4. Clinical symptoms follow the onset of abnormalities in
neurodegeneration biomarkers. Subjects who are at high
risk of cognitive impairment from AD are shown in Figure 2
with a cognitive response curve that is shifted to the left in
time (Jack et al., 2010a, 2013a). Such high-risk subjects
may harbor more significant comorbid pathologies, more
genetic risk alleles, or have low cognitive reserve (Reed
et al., 2010; Rentz et al., 2010; Roe et al., 2008; Vemuri
et al., 2011). In contrast, low-risk subjects with fewer
comorbid brain pathologies, a protective genetic profile,
and high cognitive reserve can coexist with substantial
AD pathophysiology and still maintain normal cognitive
function. Thus, cognitive response in Figure 2 is illustrated
as a zone with low- and high-risk borders (Jack et al.,
2013a). The variance in cognitive response (i.e., the range
on the y axis projection) decreases as end-stage dementia
is approached, which reflects the fact that there is rela-
tively little variation in the end-stage clinical phenotype.
The sequence of molecular and biomarker events in our
proposed ‘‘neurodegeneration-first’’ model of late-onset AD is
illustrated in Figure 2C and outlined below.
1. Age-related neurodegeneration due to medial temporal
tauopathy, non-AD pathologies, aging, or a mixture occur
first. CSF tau, MRI, FDG PET, or any combination of these
become abnormal and are denoted as a single generic
neurodegeneration biomarker curve.
2. Ab deposition arises independently in neocortical associa-
tion areas. CSF Ab42 and amyloid PET become abnormal.
3. Abopathy transforms tau-related neurodegeneration into
an aggressive process and induces its spread throughout
the neocortex (Clavaguera et al., 2009; de Calignon et al.,
2012; Frost et al., 2009; Guo and Lee, 2011; Price and
Morris, 1999). As outlined in the section on the role of Ab
in pathogenesis of AD, evidence that neurodegenerative
imaging measures can become abnormal before amyloid
biomarkers does not negate the central role of Ab in late-
onset AD in which Ab is envisioned as an accelerator of
tau-related neurodegeneration (rather than an initiator of
tau-related neurodegeneration as in early-onset AD).
4. Neurodegenerative biomarker abnormalities then
accelerate.5. Clinical symptoms follow the progression of neurodegen-
erative biomarker abnormalities.
Conclusions
AD is a slowly evolving disorder in which pathophysiological
abnormalities precede overt clinical symptoms by many years
to decades. The only in vivo window into the disease in its long
preclinical phase is biomarkers that, unlike autopsy, can be
sampled repeatedly in individual subjects over time. A thorough
understanding of the disease hinges on developing accurate,
comprehensive models of AD biomarker evolution. Designing
interventional strategies that target the right molecular pathways
at an appropriate stage in the disease depends on accurate
models of AD biomarker evolution (Fox et al., 2005; Frisoni and
Delacourte, 2009; Rinne et al., 2010; Sperling et al., 2011b).
This will lead to interventions that may be complex but are
correctly tailored to the individual patient—i.e., individualized
medicine. Finally, evolving diagnostic criteria (Albert et al.,
2011; Dubois et al., 2010; Jack et al., 2012a; McKhann et al.,
2011; Sperling et al., 2011a) must incorporate AD biomarkers
but cannot proceed effectively without accurate time-dependent
models of those biomarkers.
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